Regeneron Pharmaceuticals
Regeneron develops monoclonal antibodies and bispecific antibodies for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
10-QNov 16Latest SEC filing
Nov 12Latest story
November 2026
October 2026
September 2026
August 2026
July 2026